Genetic Technologies Transitions To A Capital Light Operating Model; With Lower Cost Operations; Continued Focus On The Co's Core Business Of "EasyDNA" And "GeneType"; Working Capital Funded By Short Term $800,000 Secured Loan; Active Channel Partners...
Genetic Technologies Transitions To A Capital Light Operating Model; With Lower Cost Operations; Continued Focus On The Co's Core Business Of "EasyDNA" And "GeneType"; Working Capital Funded By Short Term $800,000 Secured Loan; Active Channel Partners...
Genetic Technologies Transitions To A Capital Light Operating Model; With Lower Cost Operations; Continued Focus On The Co's Core Business Of "EasyDNA" And "GeneType"; Working Capital Funded By Short Term $800,000 Secured Loan; Active Channel Partners In The USA With GeneType Sales Growth; EasyDNA Sales Of $7M And Growing
基因技術轉向資本輕型經營模式；通過降低成本運營，繼續聚焦於“EasyDNA”和“GeneType”的核心業務；短期800,000美元的有擔保貸款支持運營資本；在美國有活躍的渠道夥伴，GeneType的銷售增長；EasyDNA的銷售額已達到700萬美元並在不斷增長。
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particularly in the Company's largest market in the United States) and move the Company's operations to an outsourced / collaborations approach (rather than the more expensive current in house laboratory operations).
基因技術有限公司（ASX：GTG，NASDAQ：GENE，以下簡稱“公司”或“GENE”），是基於基因組學的健康、福祉和嚴重疾病檢測領域的全球領導者，也是geneType的母公司。公司已經進行了一次運營審查，並宣佈計劃轉向資本輕型經營模式-這有望立即降低運營成本。這種資本輕型經營模式旨在聚焦於銷售增長（特別是在公司最大的市場美國），並將公司的運營轉向外包/合作伙伴方式（而不是更昂貴的現有內部實驗室運營）。
- Transition to a capital light operating model; with lower cost operations
- Continued focus on the Company's core business of "EasyDNA" and "GeneType"
- Working capital funded by short term $800,000 secured loan (from lenders including Directors)
-
Active Channel partners in the USA with geneType sales growth
- EasyDNA sales of $7m and growing
- 轉向資本輕型經營模式；通過降低成本運營
- 繼續聚焦於公司的核心業務“EasyDNA”和“GeneType”
- 運營資本由短期800,000美元的有擔保貸款支持（包括董事在內的放貸方）
- 在美國有活躍的渠道夥伴，GeneType的銷售增長
- EasyDNA的銷售額已達到700萬美元並在不斷增長
譯文內容由第三人軟體翻譯。